Journal of International Oncology››2014,Vol. 41››Issue (11): 858-865.doi:10.3760/cma.j.issn.1673-422X.2014.11.018
Previous ArticlesNext Articles
Online:
2014-12-03Published:
2015-01-20Contact:
Wang Hengxiao, Email: wanghengxiao@aliyun.comLI Chun-Ling, WANG Chao-Xia, WANG Heng-Xiao. Expression and significance of HIF-1α, PDGF and VEGF/VEGFR-2 in breast cancer[J]. Journal of International Oncology, 2014, 41(11): 858-865.
[1]SemenzaGL,WangGL.Anuclearfactorinducedbyhypoxiaviade novoproteinsynthesisbindstothehumanerythropoietingeneenhan ceratasiterequiredfortranscriptionalactivation[J].MolCellBiol, 1992,12(12):54475454. [2]HurstNJJr,NajyAJ,UstachCV,etal.Plateletderivedgrowthfac torC(PDGFC)activationbyserineproteases:implicationsforbreast cancerprogression[J].BiochemJ,2012,441(3):909918. [3]SchmidtM,VoelkerHU,KappM,etal.ExpressionofVEGFR1 (Flt1)inbreastcancerisassociatedwithVEGFexpressionandwith nodenegativetumourstage[J].AnticancerRes,2008,28(3A): 17191724. [4]BosR,vanDiestPJ,deJongJS,etal.Hypoxiainduciblefactor1α isassociatedwithangiogenesis,andexpressionofbFGF,PDGFBB, andEGFRininvasivebreastcancer[J].Histopathology,2005,46: 3136. [5]ErlerJT,BennewithKL,NicolauM,etal.Lysyloxidaseisessential forhypoxiainducedmetastasis[J].Nature,2006,440(7088): 12221226. [6]HuYL,DelayM,JahanqiriA,etal.Hypoxiainducedautophagy promotescellsurvivalandadaptationtoantiangiogenictreatmentin glioblastoma[J].CancerRes,2012,72(7):17731783. [7]ReyS,SemenzaGL.Hypoxiainduciblefactor1dependentmecha nismsofvascularizationandvascularremodeling[J].Cardiovasc Res,2010,86(2):236242. [8]GerberHP,CondorelliF,ParkJ,etal.Differentialtranscriptional regulationofthetwovascularendothelialgrowthfactorreceptorgenes. Flt1,butnotFlk1/KDR,isupregulatedbyhypoxia[J].JBiol Chem,1997,272(38):2365923667. [9]MavriaG,VercoulenY,YeoM,etal.ERKMAPKsignalingopposes Rhokinasetopromoteendothelialcellsurvivalandsproutingduring angiogenesis[J].CancerCell,2006,9:3344. [10]JiangBH,LiuLZ.AKTsignalinginregulatingangiogenesis[J]. CurrCancerDrugTar,2008,8:1926.PMID: [11]LiX,TjwaM,MoonsL,etal.Revascularizationofischemictissues byPDGFCCviaeffectsonendothelialcellsandtheirprogenitors [J].JClinInvest,2005,115:118127. [12]ZwernerJP,MayWA.DominantnegativePDGFCinhibitsgrowthof Ewingfamilytumorcelllines[J].Oncogene,2002,21:3847 3854. [13]ColtreraMD,WangJ,PorterPL,etal.Expressionofplatelet derivedgrowthfactorBchainandtheplateletderivedgrowthfactor receptorbetasubunitinhumanbreasttissueandbreastcarcinoma [J].CancerRes,1995,55(12):27032708. (收稿日期:20140811 修回日期:20141023) 国际肿瘤学杂志 2014年 11月第 41卷第 11期 JIntOncol,November2014,Vol41,No11·865· |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203. |
[3] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[4] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[5] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[6] | Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94. |
[7] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[8] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[9] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[10] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[11] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[12] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[13] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[14] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[15] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||